If you researched GLP-1 shots a year or two ago, you probably saw compounded semaglutide for $150 to $500 a month. That looked like a bargain next to Wegovy, which Novo Nordisk lists at $1,349.02 for a month's package of 4 pens. Here's the honest update as of mid-2026: those cheap compounded shots are mostly gone. The realistic path for most people is now brand-name Wegovy or Zepbound, and the good news is that the brand price has dropped a lot. (See our semaglutide guide.)
What Changed With Compounding
Compounded semaglutide is mixed by a pharmacy using the raw drug ingredient. During the 2023 to 2024 shortage, the FDA let compounding pharmacies make copies of Wegovy and Zepbound because the real thing was hard to get. That is why the low prices existed.
That window is closed. The shortage is over, and the FDA ended the special allowance for semaglutide in 2025. After a court decision on April 24, 2025, the FDA said on April 28 that the period of enforcement discretion for state-licensed pharmacies compounding under section 503A had ended. Outsourcing facilities compounding under section 503B had until May 22, 2025. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the list of bulk ingredients that large outsourcing facilities may compound from. Since the shortages ended, a state-licensed 503A compounding pharmacy may not regularly, or in inordinate amounts, make drugs that are essentially copies of a commercially available GLP-1, unless the prescriber determines and documents a significant difference for that individual patient (FDA guidance).
The One Narrow Exception
A pharmacy can still make a patient-specific version in limited cases, but only with a real medical reason. Examples include a documented allergy to an inactive ingredient in the brand product, or a dose that is not sold commercially. This is not a loophole for saving money. If a website offers you compounded semaglutide with no medical reason and no real exam, treat that as a red flag.
Cost Comparison (Mid-2026)
The gap between brand and compounded is not what it used to be, because the brand price fell.
- Wegovy manufacturer list price: $1,349.02 for a month's package of 4 pens, before any help.
- NovoCare self-pay pharmacy: $349 a month for the 0.25 mg to 2.4 mg pens if you pay cash, or from $149 a month for the Wegovy pill, which is the price at the 1.5 mg dose and rises at higher doses. Eligible new patients pay $199 for their first two fills of the 0.25 mg and 0.5 mg pens, through the end of 2026.
- Savings card: as little as $25 per month if you have commercial insurance that covers Wegovy.
- Compounded semaglutide: was about $150 to $500 per month during the shortage, but is no longer broadly available.
So the realistic comparison today is not "$300 compounded vs $1,349 brand." It is closer to "$149 to $349 brand cash price vs a compounded option most people can no longer legally get." That is a much smaller gap, and the brand comes with FDA oversight. (See our savings calculator and GLP-1 pricing guide.)
How to Make Brand-Name Affordable
You have more levers than you might think.
- Check your insurance first. If your plan covers Wegovy for weight loss, the savings card can bring your cost down to about $25 a month. See how insurance coverage works.
- Use the cash program if you are uninsured. NovoCare's self-pay pharmacy sells brand Wegovy direct for cash, with no insurance needed: from $149 a month for the pill at its starting dose, and $349 a month for the 0.25 mg to 2.4 mg pens. What you pay depends on the product, dose and eligibility.
- Check Medicare. Since July 1, 2026, a short-term CMS demonstration called the Medicare GLP-1 Bridge has covered certain GLP-1 drugs for obesity at $50 a month for eligible Part D enrollees. It covers Wegovy, Foundayo and the Zepbound KwikPen. Single-dose Zepbound vials and pens are not covered. The Bridge runs outside the normal Part D benefit and ends December 31, 2027. You are not eligible if you already get a GLP-1 through your drug plan, or if you have type 2 diabetes, moderate to severe sleep apnea, or a form of fatty liver disease called noncirrhotic MASH with moderate to advanced liver scarring. In that case your Part D plan may cover a GLP-1 for that diagnosis instead, so ask about that route. The full criteria are on CMS's Medicare GLP-1 Bridge page. Read our Medicare GLP-1 coverage guide.
- Ask about the pill. The oral semaglutide version of Wegovy was approved in December 2025 and launched in January 2026. Whether it fits you depends on dose and cost. See pill vs injection.
For more ideas, read our tips on finding affordable GLP-1 clinics.
A Quick Note on Brands
It helps to keep the names straight. Wegovy and Zepbound are approved for weight loss. Ozempic and Mounjaro are the same drugs approved for type 2 diabetes. If cost is your main worry, focus on the weight-loss brands and their savings programs, not on tracking down a compounded copy.
Bottom Line
The cheap compounded era is basically over. Brand-name Wegovy is now the realistic choice, and between the cash program, the savings card, and new Medicare coverage, it is far more affordable than it was a year ago. Talk with a licensed provider about which option fits your health and your budget.
Find a GLP-1 clinic near you to compare prices and coverage, or browse clinics by state to see what's available in your area. (Not sure if you qualify? Try our BMI calculator.)